Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

1- and 5-Year Survival for Adults with Acute Myeloid Leukaemia and 30-Day Mortality after Initial Systemic Anti-Cancer Therapy, with an Exploration of Factors Associated with Poorer Outcomes: Data from a National Registry in England, 2013-2020

Hanhua Liu, Simon J Stanworth, Sean McMphail, Mark Bishton, Brian Rous, Andrew Bacon, Thomas Coats

Blood (2023) 142 (Supplement 1): 2846.

https://doi.org/10.1182/blood-2023-179325

Published: 2023

Journal Articles

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Blood (2023) 142 (Supplement 1): 605.

https://doi.org/10.1182/blood-2023-174432

Published: 2023

Journal Articles

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

Alexander Glover, Mark Bishton, Matthew Ahearne, Kaljit Bhuller, Steve Jones, Graham P. Collins, Lindsay George, Conal McConville, Allister Foy, Catherine Hildyard, Catherine Moore, Christopher P. Fox, Claire Shannon-Lowe

Blood (2023) 142 (Supplement 1): 3660.

https://doi.org/10.1182/blood-2023-182151

Published: 2023

Journal Articles

Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors

Mark Bishton, Colin Crooks, Hanhua Liu, Lu Ban, Mary Bythell, Timothy Card, Peter Lanyon, Vasanta Nanduri, Judith Rankin, Peter Stilwell, Joe West

Blood (2022) 140 (Supplement 1): 2599–2600.

https://doi.org/10.1182/blood-2022-158999

Published: 2022

Journal Articles

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Andrew D. Zelenetz, Wojciech Jurczak, Vincent Ribrag, Kim M. Linton, Graham P. Collins, Mark Bishton, Javier López Jiménez, Bhagirathbhai Dholaria, Andrea Mengarelli, Tycel J. Phillips, Nagendra Prasad Sungala, Henry Chan, Gerardo Musuraca, Oonagh Sheehy, Junyi Yan, Weiming Xu, Michel Azoulay, Pier Luigi Zinzani

Blood (2022) 140 (Supplement 1): 3595–3597.

https://doi.org/10.1182/blood-2022-165409

Published: 2022

Journal Articles

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Mark Bishton, Corinna Woestmann, Franck Morschhauser, Toby A. Eyre, Maria Shin, Aaron Schroeder, Anton Belousov, Haocheng Li, Andrea Knapp, Michael C. Wei, Enkhtsetseg Purev, Alessia Bottos

Blood (2022) 140 (Supplement 1): 3555–3556.

https://doi.org/10.1182/blood-2022-157256

Published: 2022

Journal Articles

Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England

Joe West, Peter Stilwell, Hanhua Liu, Lu Ban, Mary Bythell, Timothy Card, Peter Lanyon, Vasanta Nanduri, Judith Rankin, Mark Bishton, Colin Crooks

Blood (2022) 140 (Supplement 1): 5469–5470.

https://doi.org/10.1182/blood-2022-159038

Published: 2022

Journal Articles

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Franck Morschhauser, Mark Bishton, Toby A. Eyre, Emmanuel Bachy, Guillaume Cartron, Loïc Ysebaert, Sabela Bobillo, Norma C. Gutierrez, L. Elizabeth Budde, Christopher P. Fox, Andrea Knapp, Manejeh Yaqub, Michael C. Wei, Carol O'Hear, Haocheng Li, Enkhtsetseg Purev, William Townsend

Blood (2021) 138 (Supplement 1): 129.

https://doi.org/10.1182/blood-2021-145694

Published: 2021

Journal Articles

Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-140774

Published: 2020

Journal Articles

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Constantine S. Tam, MD, Radhakrishnan Ramchandren, MD, Robert Chen, MD, Lionel Karlin, MD, Geoffrey Chong, MD, Wojciech Jurczak, MD PhD, Ka Lung Wu, MD PhD, Mark Bishton, MBChB, MRCP, FRCPath, PhD, Graham P. Collins, MD DPhil, Paul Eliadis, MBBS, FRACP, FRCPA, Frédéric Peyrade, MD, Edith Szafer-Glusman, PhD, Yihua Lee, PhD, Karl Eckert, BA, Jutta K. Neuenburg, MD PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 39–41.

https://doi.org/10.1182/blood-2020-134392

Published: 2020

Journal Articles

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

Mark Bishton, Pier Luigi Zinzani, MD PhD, Scott Marshall, Veronica Conteh, Alicia Rodríguez Fernández, SooKyoung Kim, Young Nam Lee

Blood (2019) 134 (Supplement_1): 4135.

https://doi.org/10.1182/blood-2019-121957

Published: 2019

Journal Articles

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Nicolas Martinez-Calle, MD MSc, Amy A. Kirkwood, MSc, Maxine Lamb, PhD, Alexandra Smith, PhD, Kate Manos, Caroline Shrubsole, MD, Nicola Gray, Sapna Ladani, MRCP, Katharine Louise Lewis, BMBS, FRCPath, MRCPath, Mark Bishton, Matthew J Ahearne, MDMBBS, Eliza A Hawkes, Wendy Osborne, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Cathy Burton, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 2849.

https://doi.org/10.1182/blood-2019-122083

Published: 2019

Journal Articles

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Blood (2019) 134 (Supplement_1): 3993.

https://doi.org/10.1182/blood-2019-125947

Published: 2019

Journal Articles

Impact of Induction Chemotherapy and Primary CNS Prophylaxis on Outcomes in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (HGBL-DH/TH) or HGBL-NOS: An International Multi-Center Retrospective Analysis

John R Balendra, MBBS, Alexander Glover, Liu Xin, Sanjay De Mel, Anand Jeyasekharan, Stephen G Jones, Mark Bishton, Chan Y. Cheah

Blood (2018) 132 (Supplement 1): 4224.

https://doi.org/10.1182/blood-2018-99-113966

Published: 2018

Journal Articles

CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement

Toby A. Eyre, Nicolas Martinez-Calle, MD #, Amy A Kirkwood, MSc, Catherine Hildyard, Murali Kesavan, Joseph Butler, Carolyn Mercer, Faouzi Djebbari, Hannah Plaschkes, John Griffith, Stephen Booth, Andrew McMillan, Mark Bishton, Christopher P. Fox, MD PhD, Graham P. Collins, MB BS DPhil, Chris Hatton

Blood (2018) 132 (Supplement 1): 1694.

https://doi.org/10.1182/blood-2018-99-111010

Published: 2018

Journal Articles

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival

Toby A. Eyre, Nicolas Martinez-Calle, MD, Catherine Hildyard, David W. Eyre, Hannah Plaschkes, Jonathan Griffith, Julia Wolf, Chris P Fox, Andrew McMillan, Mark Bishton, Graham P. Collins, MB BS DPhil, Chris Hatton, MD

Blood (2018) 132 (Supplement 1): 573.

https://doi.org/10.1182/blood-2018-99-110330

Published: 2018

Journal Articles

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Blood (2017) 130 (Supplement 1): 2025.

https://doi.org/10.1182/blood.V130.Suppl_1.2025.2025

Published: 2017

Journal Articles

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

Sarah Hartley, MBBS, MRCP, Amy Beech, Catherine Griffiths, Faith Richardson, Helen Knight, Andrew K. McMillan, FRCP, Mark Bishton, Chris P Fox

Blood (2017) 130 (Supplement 1): 3586.

https://doi.org/10.1182/blood.V130.Suppl_1.3586.3586

Published: 2017

Journal Articles

An International Multicenter Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Patients with Transplant-Eligible Mantle Cell Lymphoma

Blood (2017) 130 (Supplement 1): 4052.

https://doi.org/10.1182/blood.V130.Suppl_1.4052.4052

Published: 2017

Journal Articles

Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study

Allison Barraclough, MBBS, Musa Alzahrani, Marianne Schmidt Ettrup, Mark Bishton, Chris Van Vliet, Laurie H. Sehn, MDMPH, Vishakha Sovani, Mitchell Steven Ward, Bradley Augustson, Pedro Farinha, Jorne Lionel Biccler, MSc, Joseph M Connors, MD, David W. Scott, MD PhD FRACP, FRCPA, Kerry J Savage, MD, Tarec Christoffer El-Galaly, MD PhD, Diego Villa, MD, Chan Yoon Cheah

Blood (2017) 130 (Supplement 1): 415.

https://doi.org/10.1182/blood.V130.Suppl_1.415.415

Published: 2017

NARROW

1- and 5-Year Survival for Adults with Acute Myeloid Leukaemia and 30-Day Mortality after Initial Systemic Anti-Cancer Therapy, with an Exploration of Factors Associated with Poorer Outcomes: Data from a National Registry in England, 2013-2020

Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)

Flowrna in the Diagnosis of EBV-Related Lymphoproliferative Disease

Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors

Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England

Mosunetuzumab in Combination with Lenalidomide Has a Manageable Safety Profile and Encouraging Activity in Patients with Relapsed/Refractory Follicular Lymphoma: Initial Results from a Phase Ib Study

Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study

Rapid Infusion with CT-P10 in Patients with Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukaemia: Interim Six Month Follow-up from a European Non-Interventional Post-Authorisation Safety Study

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Impact of Induction Chemotherapy and Primary CNS Prophylaxis on Outcomes in High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements (HGBL-DH/TH) or HGBL-NOS: An International Multi-Center Retrospective Analysis

CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement

Impact of Intended and Relative Dose Intensity of RCHOP in a Large, Consecutive Cohort of Elderly DLBCL Patients: No Difference in DFS for 70-80 Years Versus >80 Years and Idi Independently Predicts Survival

Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Kinetics of T-Cell Subset Reconstitution Following Bendamustine-Containing Therapy for Low-Grade Lymphoproliferative Disease; A Population Based Analysis

An International Multicenter Retrospective Comparison of Induction Chemoimmunotherapy Regimens on Outcomes in Patients with Transplant-Eligible Mantle Cell Lymphoma

Impact of Immunohistochemistry-Defined Cell of Origin and MYC Rearrangements on Outcomes in Patients with PET-Defined Stage I/II Diffuse Large B-Cell Lymphoma Treated with R-CHOP ± Radiotherapy: An International Multi-Center Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only